Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Retrospective study of salvage treatments after covalent BTKi failure in Waldenstrom macroglobulinemia patients finds PFS of 5.8, 5.0, 6.9 and 3.9 months for chemo/immunotherapy, proteasome inhibitor, venetoclax and ncBTKi.”
Authors: Anna Maria Frustaci, Arianna Zappaterra, Andrea Galitzia, Francesco Piazza, Alessandra Tedeschi et al.
More posts featuring Robert Orlowski.
